Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab.
advanced HCC
atezolizumab
bevacizumab
lenvatinib BMI
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
22 Mar 2024
22 Mar 2024
Historique:
revised:
21
01
2024
received:
09
08
2023
accepted:
04
02
2024
medline:
22
3
2024
pubmed:
22
3
2024
entrez:
22
3
2024
Statut:
aheadofprint
Résumé
Overweight is a negative prognostic factor in the general population in the long term. However, the role of body mass index (BMI) in the short-mid term in advanced tumours is unclear. The present analysis investigates the role of BMI weight classes in a large sample of patients affected by HCC and receiving atezolizumab plus bevacizumab or lenvatinib as first-line treatment. The cohort included consecutive patients affected by BCLC-c and BCLC-B HCC patients from a multicenter international study group who received atezolizumab plus bevacizumab or lenvatinib as first-line therapy. Population was stratified according to the BMI in under-, over- and normal-weight according to the conventional thresholds. The primary objective of the study was to evaluate the prognostic and predictive impact of BMI in patients affected by advanced or intermediate HCC. Survival curves were estimated using the product-limit method of Kaplan-Meier. The role of stratification factors was analysed with log-rank tests. 1292 consecutive patients with HCC were analysed. 466 (36%) patients were treated with lenvatinib and 826 (64%) patients were treated with atezolizumab plus bevacizumab. In the atezolizumab plus bevacizumab arm, 510 (62%) patients were normal-weight, 52 (6%) underweight and 264 (32%) overweight. At the univariate analysis for OS, underweight patients had significantly shorter OS compared to normal-weight patients, whereas no differences were found between normal-weight versus overweight. Multivariate analysis confirmed that underweight patients had significantly shorter OS compared to normal-weight patients (HR: 1.7; 95% CI: 1.0-2.8; p = .0323). In the lenvatinib arm, 26 patients (5.6%) were categorized as underweight, 256 (54.9%) as normal-weight, and 184 (39.5%) as overweight. At the univariate analysis for OS, no significant differences were found between normal-weight versus underweight and between normal-weight versus overweight, which was confirmed at multivariate analysis. Our analysis highlighted a prognostic role of BMI in a cohort of patients with advanced HCC who received atezolizumab plus bevacizumab, while no prognostic role for low BMI was apparent in patients who received lenvatinib.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6. doi:10.1038/s41572-020-00240-3
Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378‐390. doi:10.1056/NEJMoa0708857
Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia‐Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double‐blind, placebo‐controlled trial. Lancet Oncol. 2009;10(1):25‐34. doi:10.1016/S1470-2045(08)70285-7
Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first‐line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non‐inferiority trial. Lancet. 2018;391:1163‐1173.
Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894‐1905. doi:10.1056/NEJMoa1915745
Abou‐Alfa GK, Chan SL, Kudo M, et al. Phase 3 randomized, open‐label, multicenter study of tremelimumab and durvalumab as first‐line therapy in patients with unresectable hepatocellular carcinoma: HIMALAYA. J Clin Oncol. 2022;40:379. doi:10.1200/JCO.2022.40.4_suppl.379
Kelley RK, Rimassa L, Cheng AL, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC‐312): a multicentre, open‐label, randomized, phase 3 trial. Lancet Oncol. 2022;23(8):995‐1008. doi:10.1016/S1470-2045(22)00326-6
Finn R, Kudo M, Merle P, et al. Primary results from the phase 3 LEAP‐002 study: lenvatinib plus pembrolizumab versus Lenvatinib as first‐line (1L) therapy for advanced hepatocellular carcinoma (aHCC). Ann Oncol. 2022;33:S808‐S869.
Qin S, Chan LS, Gu S, et al. Camrelizumab I plus rivoceranI(R) vs. sorafenib (S) as first‐line therapy for unresectable hepatocellular carcinoma (uHCC): a randomized, phase III trial. Ann Oncol. 2022;33:S1401‐S1402.
Casadei‐Gardini A, Rimini M, Kudo M, Shimose S, Tada T, Suda G, Goh M, J, Jefremow A, Scartozzi M, Cabibbo G, Campani C, Tamburini E, Tovoli F, Ueshima K, Aoki T, Iwamoto H, Torimura T, Kumada T, Hiraoka A, Atsukawa M, Itobayashi E, Toyoda H, Sakamoto N, Sho T, Kang W, Siebler J, Neurath M, F, Burgio V, Cascinu S: REal life study of Lenvatinib therapy for HepAtocellular carcinoma: RELEVANT study. Liver Cancer 2022;11:527–539. 10.1159/000525145
Rimini M, Shimose S, Lonardi S, et al. Lenvatinib versus sorafenib as first‐line treatment in hepatocellular carcinoma: a multi‐institutional matched case‐control study. Hepatol Res. 2021;51(12):1229‐1241. doi:10.1111/hepr.13718
Casadei‐Gardini A, Scartozzi M, Tada T, et al. Lenvatinib versus sorafenib in first‐line treatment of unresectable hepatocellular carcinoma: an inverse probability of treatment weighting analysis. Liver Int. 2021;41(6):1389‐1397. doi:10.1111/liv.14817
Burgio V, Iavarone M, Di Costanzo GG, et al. Real‐life clinical data of lenvatinib versus sorafenib for unresectable hepatocellular carcinoma in Italy. Cancer Manag Res. 2021;13:9379‐9389. doi:10.2147/CMAR.S330195
Rapposelli IG, Shimose S, Kumada T, et al. Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma. ESMO Open. 2021;6(4):100190. doi:10.1016/j.esmoop.2021.100190
Rimini M, Kang W, Burgio V, et al. Validation of the easy‐to‐use lenvatinib prognostic (LEP) index to predict prognosis in advanced hepatocellular carcinoma patients treated with Lenvatinib. Hepatol Res. 2022;52(12):1050‐1059. doi:10.1111/hepr.13824
Rimini M, Kudo M, Tada T, et al. Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with Lenvatinib. ESMO Open. 2021;6(6):100330. doi:10.1016/j.esmoop.2021.100330
Rimini M, Rimassa L, Ueshima K, et al. Atezolizumab plus bevacizumab versus Lenvatinib or sorafenib in non‐viral unresectable hepatocellular carcinoma: an international propensity score matching analysis. ESMO Open. 2022;7(6):100591. doi:10.1016/j.esmoop.2022.100591
Rimini M, Persano M, Tada T, et al. Real‐world data for atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: how does adherence to the IMbrave150 trial inclusion criteria impact prognosis? Target Oncol. 2023;18(2):221‐233. doi:10.1007/s11523-023-00953-x
Lennon H, Sperrin M, Badrick E, Renehan AG. The obesity paradox in cancer: a review. Curr Oncol Rep. 2016;18(9):56. doi:10.1007/s11912-016-0539-4
Cortellini A, Bersanelli M, Santini D, et al. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein1 (PD‐1)/Programmed cell death‐ligand 1 (PD‐L1) checkpoint inhibitors: a multicentre analysis of immune‐related adverse events. Eur J Cancer. 2020;128:17‐26. doi:10.1016/j.ejca.2019.12.031
Santoni M, Massari F, Bracarda S, et al. Body mass index in patients treated with cabozantinib for advanced renal cell carcinoma: a new prognostic factor? Diagnostics. 2021;11:138. doi:10.3390/diagnostics11010138
Richtig G, Hoeller C, Wolf M, et al. Body mass index may predict the response to ipilimumab in metastatic melanoma: an observational multi‐centre study. PLoS One. 2018;13:e0204729. doi:10.1371/journal.pone.0204729
Roccuzzo G, Moirano G, Fava P, Maule M, Ribero S, Quaglino P. Obesity and immune‐checkpoint inhibitors in advanced melanoma: a meta‐analysis of survival outcomes from clinical studies. Semin Cancer Biol. 2023;91:27‐34. doi:10.1016/j.semcancer.2023.02.010
Chen J, Lu L, Qu C, et al. Body mass index, as a novel predictor of hepatocellular carcinoma patients treated with anti‐PD‐1 immunotherapy. Front Med (Lausanne). 2022;9:981001. doi:10.3389/fmed.2022.981001
Vithayathil M, D'Alessio A, Fulgenzi CAM, et al. Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma. Hepatol Int. 2023;17(4):904‐914. doi:10.1007/s12072-023-10491-3
Freites‐Martinez A, Santana N, Arias‐Santiago S, Viera A. Using the Common Terminology Criteria for Adverse Events–CTCAE–Version 5.0 to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed). 2021;112(1):90‐92. doi:10.1016/j.ad.2019.05.009
Bravo AC, Lobo‐Martins SL, Vendrell I, et al. 1320P impact of body mass index (BMI) in non‐small cell lung cancer patients treated with anti PD‐1 immunotherapy (IO): a retrospective cohort study. Ann Oncol. 2020;31:S852. doi:10.1016/j.annonc.2020.08.1634
McQuade JL, Daniel CR, Hess KR, et al. Association of body‐mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 2018;19:310‐322. doi:10.1016/S1470-2045(18)30078-0
Zhang C, Yue C, Herrmann A, et al. STAT3 activation‐induced fatty acid oxidation in CD8 + T effector cells is critical for obesity‐promoted breast tumor growth. Cell Metab. 2020;31:148‐161.e5. doi:10.1016/j.cmet.2019.10.013
Noh M. Interleukin‐17A increases leptin production in human bone marrow mesenchymal stem cells. Biochem Pharmacol. 2012;83:661‐670.
Matarese G, La Rocca C, Moon HS, et al. Selective capacity of metreleptin administration to reconstitute CD4+ T‐cell number in females with acquired hypoleptinemia. Proc Natl Acad Sci USA. 2013;110:E818‐E827.
Saucillo DC, Gerriets VA, Sheng J, Rathmell JC, MacIver NJ. Leptin metabolically licenses T cells for activation to link nutrition and immunity. J Immunol. 2014;192:136‐144.
Naylor C, Petri WA Jr. Leptin regulation of immune responses. Trends Mol Med. 2016;22:88‐98.
Rodriguez L, Graniel J, Ortiz R. Effect of leptin on activation and cytokine synthesis in peripheral blood lymphocytes of malnourished infected children. Clin Exp Immunol. 2007;148:478‐485.
Mehler PS, Eckel RH, Donahoo WT. Leptin levels in restricting and purging anorectics. Int J Eat Disord. 1999;26:189‐194.
Song Y, Du C, Zhang W, et al. Body mass index and age are additional prognostic factors in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. Urol Oncol. 2016;34(6):258.e15‐258.e22. doi:10.1016/j.urolonc.2015.12.008
Wu SE, Charles HW, Park JS, Goldenberg AS, Deipolyi AR. Obesity conveys poor outcome n patients with hepatocellular carcinoma treated by transarterial chemoembolization. Diagn Interv Imaging. 2017;98:37‐42.
Liu X, Xu J. Body mass index and waistline are predictors of survival for hepatocellular carcinoma after hepatectomy. Med Sci Monit. 2015;21:2203‐2209.
Mathur A, Franco ES, Leone JP, et al. Obesity portends increased morbidity and earlier recurrence following liver transplantation for hepatocellular carcinoma. HPB (Oxford). 2013;15:504‐510.
Abdel‐Rahman O. Impact of baseline characteristics on outcomes of advanced HCC patients treated with sorafenib: a secondary analysis of a phase III study. J Cancer Res Clin Oncol. 2018;144:901‐908.
Nishikawa H, Arimoto A, Wakasa T, Kita R, Kimura T, Osaki Y. The relation between obesity and survival after surgical resection of hepatitis C virus‐related hepatocellular carcinoma. Gastroenterol Res Pract. 2013;2013:430438.
Nishikawa H, Osaki Y, Takeda H, et al. Efect of body mass index on survival after curative therapy for non‐B non‐C hepatocellular carcinoma. J Gastrointestin Liver Dis. 2013;22:173‐181.
Mouchli M, Reddy S, Gerrard M, Boardman L, Rubio M. Usefulness of neutrophil‐to‐lymphocyte ratio (NLR) as a prognostic predictor after treatment of hepatocellular carinoma. Ann Hepatol. 2021;22:100249. doi:10.1016/j.aohep.2020.08.067
Davar D, Kirkwood JM. PD‐1 immune checkpoint inhibitors and immune‐related adverse events. JAMA Oncol. 2019;5:942. doi:10.1001/jamaoncol.2019.0413
Xu H, Cao D, He A, Ge W. The prognostic role of obesity is independent of sex in cancer patients treated with immune checkpoint inhibitors: a pooled analysis of 4090 cancer patients. Int Immunopharmacol. 2019;74:105745. doi:10.1016/j.intimp.2019.105745